Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | CDC25B | P30305 | 2/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | ACR | P10323 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872653 | 0.88 | ALDH1A1 (0.43) | KDM4EFGFR4KMT2APPARGMEN1 | |
| SCHEMBL3866786 | 0.88 | KDM4E (0.48) | KDM4EATMKMT2APPARGMEN1 | |
| SCHEMBL1779104 | 0.88 | AURKA (0.43) | PTPN2PTPN1CDC25BPTPN6PTPN11 | |
| SCHEMBL3871522 | 0.87 | P2RY14 (0.47) | KDM4EATMKMT2APPARGMEN1 | |
| SCHEMBL3869683 | 0.86 | FGFR4 (0.40) | PTPN2PTPN1CDC25BPTPN6PTPN11 | |
| SCHEMBL3872706 | 0.86 | KCNMA1 (0.38) | PTPN2PTPN1CDC25BPTPN6PTPN11 | |
| SCHEMBL3866586 | 0.86 | POLB (0.42) | KDM4EFGFR4KMT2AMEN1 | |
| SCHEMBL3870804 | 0.84 | NPC1 (0.45) | KMT2AMEN1 | |
| SCHEMBL1778845 | 0.84 | PPARG (0.37) | PTPN2PTPN1CDC25BPTPN6PTPN11 | |
| SCHEMBL3872962 | 0.83 | CYP1A2 (0.48) | KDM4EATMKMT2APPARGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904503-B1 | 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-11-06 | — | — | EP | disclosed |
| US-20090149457-A1 | 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-06-11 | — | — | US | disclosed |
| EP-1904503-A1 | 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007009898-A1 | 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149457-A1 | 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors | CCNH, PDK1, MAP3K5 | PTPN2 2205/4885PTPN1 2174/4885CDC25B 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.